OncoMatch/Clinical Trials/NCT06810375
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
Is NCT06810375 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) and Intercostal nerve block for lung cancers.
Treatment: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) · Intercostal nerve block — This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The George Washington University Hospital · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06810375 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify